Table 3 Type specific prevalence of oncogenic HPV infection in women with (1) ASC-H/HSIL cytology * , (2) histologically-confirmed grade CIN 2 and (3) ≥ CIN 3
From: Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand
ASC-H/HSIL cytology*†(N=594) | CIN 2†(N=152) | ≥ CIN 3†‡(N=223) | |||||||
|---|---|---|---|---|---|---|---|---|---|
HR HPV type | n | % | 95% CI | n | % | 95% CI | n | % | 95% CI |
16 | 262 | 44.1 | (40.1 - 48.2) | 70 | 46.1 | (37.9 - 54.3) | 122 | 54.7 | (47.9 - 61.4) |
52 β | 100 | 16.8 | (13.9 - 20.1) | 24 | 15.8 | (10.4 - 22.6) | 47 | 21.1 | (15.9 - 27.0) |
31 | 90 | 15.2 | (12.4 - 18.3) | 37 | 24.3 | (17.8 - 32.0) | 27 | 12.1 | (8.1 - 17.1) |
33 | 70 | 11.8 | (9.3 - 14.7) | 26 | 17.1 | (11.5 - 24.0) | 21 | 9.4 | (5.9 - 14.0) |
18 | 67 | 11.3 | (8.8 - 14.1) | 16 | 10.5 | (6.1 - 16.5) | 32 | 14.3 | (10.0 - 19.6) |
58 | 60 | 10.1 | (7.8 - 12.8) | 21 | 13.8 | (8.8 - 20.3) | 21 | 9.4 | (5.9 - 14.0) |
51 | 54 | 9.1 | (6.9 - 11.7) | 12 | 7.9 | (4.1 - 13.4) | 24 | 10.8 | (7.0 - 15.6) |
39 | 39 | 6.6 | (4.7 - 8.9) | 14 | 9.2 | (5.1 - 15.0) | 12 | 5.4 | (2.8 - 9.2) |
45 | 29 | 4.9 | (3.3 - 6.9) | 4 | 2.6 | (0.7 - 6.6) | 13 | 5.8 | (3.1 - 9.8) |
59 | 26 | 4.4 | (2.9 - 6.3) | 5 | 3.3 | (1.1 - 7.5) | 12 | 5.4 | (2.8 - 9.2) |
35 | 25 | 4.2 | (2.7 - 6.2) | 12 | 7.9 | (4.1 - 13.4) | 5 | 2.2 | (0.7 - 5.2) |
56 | 20 | 3.4 | (2.1 - 5.2) | 3 | 2.0 | (0.4 - 5.7) | 7 | 3.1 | (1.3 - 6.4) |
68 | 14 | 2.4 | (1.3 - 3.9) | 4 | 2.6 | (0.7 - 6.6) | 4 | 1.8 | (0.5 - 4.5) |
16 and/or 18 | 314 | 52.9 | (48.8 - 56.9) | 80 | 52.6 | (44.4 - 60.8) | 148 | 66.4 | (59.8 - 72.5) |
16 and/or 18 (alone) | 112 | 18.9 | (15.8 - 22.2) | 33 | 21.7 | (15.4 - 29.1) | 49 | 22.0 | (16.7 - 30.0) |
OHR | 201 | 33.8 | (30.0 - 37.8) | 65 | 42.8 | (34.8 - 51.0) | 63 | 28.3 | (22.3 - 34.6) |
Single HR HPV | 277 | 46.7 | (42.6 - 50.7) | 70 | 46.1 | (37.9 - 54.3) | 117 | 52.5 | (45.7 - 59.2) |
Any HR HPV | 515 | 86.7 | (83.7 - 89.3) | 145 | 95.4 | (90.7 - 98.1) | 211 | 94.6 | (90.1 - 97.2) |